

Edgar Filing: AMPLIDYNE INC - Form 8-K

AMPLIDYNE INC
Form 8-K
November 10, 2005

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):
November 9, 2005 (November 4, 2005)

AMPLIDYNE, INC.
(Exact name of registrant as specified in its charter)

Delaware

(State or Other
Jurisdiction of
Incorporation)

0-21931

(Commission File No.)

22-3440510

(IRS Employer
Identification No.)

59 LaGrange Street
Raritan, New Jersey 08869

(Address of Principal Executive Office)

(908) 253-6870

Registrant's telephone number, including area code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

Section 5 - Corporate Governance and Management

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On November 4, 2005, the Registrant amended its Certificate of Incorporation to (a) change its name to Wi-Tron, Inc., (b) increase the authorized shares of common stock, \$.0001 par value, from 25,000,000 shares to 100,000,000 shares of common stock, and (c) increase the authorized shares of preferred stock, \$.0001 par value, from 1,000,000 to 5,000,000 shares of

Edgar Filing: AMPLIDYNE INC - Form 8-K

preferred stock.

Section 9 - Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits.

(c) Exhibits.

3.1 Certificate of Amendment to Certificate of Incorporation.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereto duly authorized.

AMPLIDYNE, INC.

Date: November 4, 2005

By: /s/ John Chase Lee

John Chase Lee, President